Diabetes treatment approach replicates pancreatic functions with bioink and 3D bioprinting technology
A research team has successfully developed an innovative platform for diabetes treatment using bioink derived from pancreatic ...
PMLive2h
FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours
The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...
Science Daily10d
Shaping the future of diabetes treatment with 3D bioprinting technology
Diabetes is a metabolic disorder caused by dysfunction in the pancreas, the organ responsible for regulating blood sugar levels. Within the pancreas, islet cells secrete insulin to lower blood sugar.
Medscape20d
A Common Pancreatic Condition That Few Have Heard Of
The most common pathology affecting the pancreas is excess intra ... the islets of Langerhans on the endocrine side. Additionally, when functional pancreatic cells die, particularly acinar cells ...
The American Journal of Managed Care4d
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...
Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors
Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.
News Medical on MSN4d
Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...